Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer

Por Patel, Shiven B, Gill, David, Garrido-Laguna, Ignacio
Publicado no Onco Targets Ther (2015)

A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency

Por Rengifo-Cam, William, Jasperson, Kory, Garrido-Laguna, Ignacio, Colman, Howard, Scaife, Courtney, Samowitz, Wade, Samadder, N. Jewel
Publicado no ACG Case Rep J (2017)

N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012

Por Garrido-Laguna, Ignacio, Tometich, Danielle, Hu, Nan, Ying, Jian, Geiersbach, Katherine, Whisenant, Jonathan, Wang, Kai, Ross, Jeffrey S., Sharma, Sunil
Publicado no Oncoscience (2015)

A framework for genomic biomarker actionability and its use in clinical decision making

Por Vidwans, Smruti J., Turski, Michelle L., Janku, Filip, Garrido-Laguna, Ignacio, Munoz, Javier, Schwab, Richard, Subbiah, Vivek, Rodon, Jordi, Kurzrock, Razelle
Publicado no Oncoscience (2014)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

Por Janku, Filip, Lee, J. Jack, Tsimberidou, Apostolia M., Hong, David S., Naing, Aung, Falchook, Gerald S., Fu, Siqing, Luthra, Rajyalakshmi, Garrido-Laguna, Ignacio, Kurzrock, Razelle
Publicado em 2011

Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Treated in a Phase I Clinic

Por Janku, Filip, Tsimberidou, Apostolia M., Wang, Xuemei, Hong, David S., Naing, Aung, Gong, Jing, Garrido-Laguna, Ignacio, Parsons, Henrique A., Zinner, Ralph G., Kurzrock, Razelle
Publicado em 2011

KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

Por Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Nguyen, Ly M., Falchook, Gerald S., Fu, Siqing, Wheler, Jenifer J., Luthra, Rajyalakshmi, Naing, Aung, Wang, Xuemei, Kurzrock, Razelle
Publicado em 2012

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

Por Hidalgo, Manuel, Bruckheimer, Elizabeth, Rajeshkumar, N.V., Garrido-Laguna, Ignacio, De Oliveira, Elizabeth, Rubio-Viqueira, Belen, Strawn, Steven, Wick, Michael J., Martell, James, Sidransky, David
Publicado no Mol Cancer Ther (2011)

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer

Por Villarroel, Maria C., Rajeshkumar, N.V., Garrido-Laguna, Ignacio, De Jesus-Acosta, Ana, Jones, Siân, Maitra, Anirban, Hruban, Ralph H., Eshleman, James R., Klein, Alison, Laheru, Daniel, Donehower, Ross, Hidalgo, Manuel
Publicado em 2010

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

Por Janku, Filip, Tsimberidou, Apostolia M., Garrido-Laguna, Ignacio, Wang, Xuemei, Luthra, Rajyalakshmi, Hong, David S., Naing, Aung, Falchook, Gerald S., Moroney, John W., Piha-Paul, Sarina A., Wheler, Jennifer J., Moulder, Stacy L., Fu, Siqing, Kurzrock, Razelle
Publicado em 2011

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

Por Janku, Filip, Wheler, Jennifer J., Westin, Shannon N., Moulder, Stacy L., Naing, Aung, Tsimberidou, Apostolia M., Fu, Siqing, Falchook, Gerald S., Hong, David S., Garrido-Laguna, Ignacio, Luthra, Rajyalakshmi, Lee, J. Jack, Lu, Karen H., Kurzrock, Razelle
Publicado em 2012

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

Por Janku, Filip, Wheler, Jennifer J., Naing, Aung, Stepanek, Vanda M., Falchook, Gerald S., Fu, Siqing, Garrido-Laguna, Ignacio, Tsimberidou, Apostolia M., Piha-Paul, Sarina A., Moulder, Stacy L., Lee, J. Jack, Luthra, Rajyalakshmi, Hong, David S., Kurzrock, Razelle
Publicado em 2012

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

Por Feldmann, Georg, Mishra, Anjali, Bisht, Savita, Karikari, Collins, Garrido-Laguna, Ignacio, Rasheed, Zeshaan, Ottenhof, Niki A, Dadon, Tikva, Alvarez, Hector, Fendrich, Volker, Rajeshkumar, NV, Matsui, William, Brossart, Peter, Hidalgo, Manuel, Bannerji, Rajat, Maitra, Anirban, Nelkin, Barry D
Publicado em 2011

Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predicts poor survival and resistance to gemcitabine in patients with pancreatic cancer

Por Garrido-Laguna, Ignacio, Uson, Maria, Rajeshkumar, N.V., Tan, Aik Choon, de Oliveira, Elizabeth, Karikari, Collins, Villaroel, Maria C., Salomon, Ana, Taylor, Gretchen, Sharma, Rajni, Hruban, Ralph H., Maitra, Anirban, Laheru, Daniel, Rubio-Viqueira, Belén, Jimeno, Antonio, Hidalgo, Manuel
Publicado em 2011

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Por Park, Haeseong, Garrido-Laguna, Ignacio, Naing, Aung, Fu, Siqing, Falchook, Gerald S., Piha-Paul, Sarina A., Wheler, Jennifer J., Hong, David S., Tsimberidou, Apostolia M., Subbiah, Vivek, Zinner, Ralph G., Kaseb, Ahmed O., Patel, Shreyaskumar, Fanale, Michelle A., Velez-Bravo, Vivianne M., Meric-Bernstam, Funda, Kurzrock, Razelle, Janku, Filip
Publicado no Oncotarget (2016)